SWOG clinical trial number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Open
Phase
Abbreviated Title
Phase III Trial Comparing Standard of Care with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Status Notes
CTSU/AHOD2131 has been endorsed and activated by SWOG, effective 02/01/2024. CTSU/AHOD2131 was activated by Adolescent and Young Adult, effective 04/28/2023.
Activated
04/28/2023
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Lymphoma
Immunomolecular Therapeutics
Eligibility Criteria Expand/Collapse
Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/A151804
ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OF IMMUNE-RELATED ADVERSE EVENTS
Research Committee(s)
Immunomolecular Therapeutics
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Leukemia
Lung Cancer
Lymphoma
Melanoma
Myeloma
Early Therapeutics & Rare Cancers
Activated
06/15/2020
Open
Phase